
Sign up to save your podcasts
Or


Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world stage, says Orum Therapeutics founder and CEO SJ Lee in conversation with BioCentury Executive Editor Jeff Cranmer on The BioCentury Show.
Lee’s company, a leader in degrader-antibody conjugates, provides an example of how to run that playbook. Lee also spoke about where Korea fits in East Asia’s life sciences scene, how Western players can get to know the Korean biopharma industry, and what’s next for Orum’s pipeline. This episode of The BioCentury Show was sponsored by Faron.
View full story: https://www.biocentury.com/article/656147
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment
02:11 - Korea's Biotech Ecosystem
09:57 - Evolution of Korean Biotech
16:08 - Orum's Degrader Antibody Conjugates
By BioCentury4.6
1010 ratings
Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world stage, says Orum Therapeutics founder and CEO SJ Lee in conversation with BioCentury Executive Editor Jeff Cranmer on The BioCentury Show.
Lee’s company, a leader in degrader-antibody conjugates, provides an example of how to run that playbook. Lee also spoke about where Korea fits in East Asia’s life sciences scene, how Western players can get to know the Korean biopharma industry, and what’s next for Orum’s pipeline. This episode of The BioCentury Show was sponsored by Faron.
View full story: https://www.biocentury.com/article/656147
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment
02:11 - Korea's Biotech Ecosystem
09:57 - Evolution of Korean Biotech
16:08 - Orum's Degrader Antibody Conjugates

4,358 Listeners

1,186 Listeners

425 Listeners

355 Listeners

2,325 Listeners

1,448 Listeners

235 Listeners

124 Listeners

325 Listeners

86 Listeners

34 Listeners

208 Listeners

144 Listeners

18 Listeners

47 Listeners